AI-powered search

Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib?

Featuring Cheri Frey, MD |

Assistant Professor, Dermatology & Residency Program Director 
Director of Cosmentic Dermatology
Howard University
Washington, DC

| Published June 01, 2024

Loading...

Related Media

Powered by Polaris TM
Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved